BridgeBio Oncology Therapeutics Inc. Stock Analysis & AI Score
BridgeBio Oncology Therapeutics Inc. (BBOT) has an ST Score of 37.8 (C), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $19.00 price target (+376.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
BridgeBio Oncology Therapeutics Inc. (BBOT) has an ST Score of 37.8 (C), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $19.00 price target (+376.2% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD
All factor grades
- ForecastA
- Financial StrengthB-
- ValuationC
- ProfitabilityC
- GrowthD+
- MomentumD
- Piotroski0/9
Contact
BBOT stock: frequently asked questions
What is BBOT's ST Score?
BridgeBio Oncology Therapeutics Inc. (BBOT) has an ST Score of 37.8 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BBOT a buy, hold, or sell?
Analysts rate BBOT a Buy, with a price target of $19.00 (+376.2% vs the current price). Our ST Score grades it C (37.8/100). The ST Score is a data-driven signal, not a recommendation.
What are BBOT's factor grades?
Valuation C, Profitability C, Financial Strength B-, Momentum D, Growth D+, Forecast A.
What is BBOT's valuation grade?
BridgeBio Oncology Therapeutics Inc. (BBOT) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BBOT's growth grade?
BridgeBio Oncology Therapeutics Inc. (BBOT) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BBOT's profitability grade?
BridgeBio Oncology Therapeutics Inc. (BBOT) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BBOT's financial strength grade?
BridgeBio Oncology Therapeutics Inc. (BBOT) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BBOT?
The average analyst price target for BridgeBio Oncology Therapeutics Inc. (BBOT) is $19.00 from 8 analysts, which is +376.2% versus the recent price of $3.99.
What is BBOT's Piotroski score?
BridgeBio Oncology Therapeutics Inc. (BBOT) has a Piotroski F-Score of 0 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.